Gabriel Eckenstein

Spine-related pain is taking a huge toll on our society: more bed-days, more days off work, and at a greater financial cost to westernized healthcare than any other condition. We’re on a mission to ease this burden through superior biologics for better spinal fusions. We believe that a greater quality and quantity of science holds the key to easing the burden of back surgery. Every day, we put our 150 years’ combined research experience to work in achieving this, which includes: 10 well-controlled Level I-III clinical trials initiated. >25 orthobiologics-related patents. >400 patients evaluated in Level I, randomized controlled clinical trials. >15,000 patients successfully treated. Today, nearly 1 in 5 spinal fusions fail. But what can we do to change this situation - for the benefit of patients, surgeons and our wider society? This is the question that drives us at Kuros. Every day our team works across three continents to unlock the hidden secrets of bone healing through our research, development & technology program: Project Fusion. To deliver the ideal bone graft, we believe you need the highest quality & quantity of scientific evidence behind it. Which is why Project Fusion brings together an unprecedented blend of scientific, pre-clinical and clinical studies – all aimed at making the unpredictable…predictable. CONTACT KUROS TO FIND OUT MORE >>>>

Leading Technology for the Encapsulation of nucleic acids, biomolecules, and other APIs. Our technology solves your current encapsulation challenges. We offer highly flexible GMP manufacturing solutions for your genetic payloads and other molecules, making manufacturing of transfection material a highly flexible and commercially viable proposition. LEON utilises its’ proprietary nano technology platform for the continuous manufacturing of SMART nanoparticles (ranging from surface stablilised polymeric through to lipid nanoparticles (LNPs) and liposomes). The Company is working with world class industry partners for both process and product development.

Spine-related pain is taking a huge toll on our society: more bed-days, more days off work, and at a greater financial cost to westernized healthcare than any other condition. We’re on a mission to ease this burden through superior biologics for better spinal fusions. We believe that a greater quality and quantity of science holds the key to easing the burden of back surgery. Every day, we put our 150 years’ combined research experience to work in achieving this, which includes: 10 well-controlled Level I-III clinical trials initiated. >25 orthobiologics-related patents. >400 patients evaluated in Level I, randomized controlled clinical trials. >15,000 patients successfully treated. Today, nearly 1 in 5 spinal fusions fail. But what can we do to change this situation - for the benefit of patients, surgeons and our wider society? This is the question that drives us at Kuros. Every day our team works across three continents to unlock the hidden secrets of bone healing through our research, development & technology program: Project Fusion. To deliver the ideal bone graft, we believe you need the highest quality & quantity of scientific evidence behind it. Which is why Project Fusion brings together an unprecedented blend of scientific, pre-clinical and clinical studies – all aimed at making the unpredictable…predictable. CONTACT KUROS TO FIND OUT MORE >>>>

Leading Technology for the Encapsulation of nucleic acids, biomolecules, and other APIs. Our technology solves your current encapsulation challenges. We offer highly flexible GMP manufacturing solutions for your genetic payloads and other molecules, making manufacturing of transfection material a highly flexible and commercially viable proposition. LEON utilises its’ proprietary nano technology platform for the continuous manufacturing of SMART nanoparticles (ranging from surface stablilised polymeric through to lipid nanoparticles (LNPs) and liposomes). The Company is working with world class industry partners for both process and product development.

Beyond Capital Fund is an evergreen impact investment fund that invests in for-profit, early-stage companies throughout East Africa and India. The fund invests in businesses that are focused on greater access to health care, sanitation, clean energy, agriculture & food security, and financial inclusion, which can increase the quality of life for consumers living at the bottom of the economic pyramid. Though the fund seeks market-rate financial returns, Beyond Capital is structured as a nonprofit, which permits the organization to emphasize fidelity to its social mission alongside its financial mandate. Since its founding in 2009, Beyond Capital has reached a growing 8 million people, including 5.8 million women, living in underserved communities.

Leukocare AG, located in Martinsried/Munich, Germany and Milford, MA, USA, is the leading innovator for drug product development of biologics for many modalities with services specializing in drug product development tailored to the target product profile. Leukocare provides superior stabilization and optimal formulation of the drug product to increase shelf life and improve logistics, reducing risks in drug development programs. Leukocare is different from other companies in that bioinformatics and biostatistics-based approaches are used in the Design of Experiment (DoE) to explore a broader design space than conventional methods in order to find the best combination of excipients. This is achieved by synergizing in-silico methods with wet lab experiments, which reduces the number of experiments needed or the need for high throughput, resulting in the use of less drug substance and reduced development time. Our strength is that we draw on our database of over 100+ regulatory approved excipients, reducing the hurdles later in the clinic. In addition to formulation development services, Leukocare offers analytical and bioinformatics services for already in-process drug discovery and development projects. Our robust analytical expertise is applied to services ranging from particle characterization, stability and molecular integrity analysis, and long-term stability prediction to non-GMP filling for toxicology studies or molecular modeling and to help in candidate selection of drug substances.

Since 1999 Thomas Bachmann and Gabriel Eckenstein have been dealing and consulting in Japanese art. Thomas Bachmann and Gabriel Eckenstein launched their international business in 1999. They specialize in painting, calligraphy, and ceramics from the Momoyama up to the Taisho Period, 16th to early 20th centuries. Dealing always was and still is their main business. Nevertheless consulting and curating have become more and more important, for both private clients, and museums. Whereas consulting can be a short term assignment in the process of decision shaping and decision making, curating tends to be a long term involvement with a collection. Depending on the client’s vision, we can help the client to create strategies to build, to improve, or to dissolve a collection. BachmannEckenstein | JapaneseArt are based in Basel the cultural capital of Switzerland, right in the center of the old continent and half way between Japan and the United States. They are regular participants and exhibitors of New York Asia Week. Exhibitions in their gallery in a 19th century residential building are held occasionally.